Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Nuvation Bio Inc. reported revenue of $63M, up 699.0% year over year. Operating margin was -338.7% and net margin -325.3%, on a free-cash-flow margin of -288.4% with capital expenditure at 12.7% of revenue. Every figure is computed directly from NUVB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $63M | -338.7% | -325.3% |
| FY2024 | $8M | -7527.3% | -7213.8% |
| FY2023 | $0M | n/a | n/a |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
How does NUVB compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.